Analysis of efficacy and safety of multiple intravenous infusion of anti-tumour necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis;Porównanie skuteczności i bezpieczeństwa wielokrotnych dożylnych infuzji monoklonalnego przeciwciała przeciwko tnf-alfa (Remicade) skojarzonych z metotreksatem z aczonym leczeniem aurotiomalatem sodu i metylprednizolonem podawanymi domiȩśniowo pacjentom z reumatoidalnym zapaleniem stawów

Polskie Archiwum Medycyny Wewnetrznej

Volumn 108, Issue 5, 2002, Pages 1055-1063

  Wiland, Piotr ^a   Glowska, Agnieszka ^a   Chlebicki, Arkadiusz ^a   Szechiński, Jacek ^b  

^a Szpital Kolejowego   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Gold treatment; Methotrexate, infliximab; Methylprednisolone; Reumatoid arthritis

Indexed keywords

AUROTHIOMALATE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; LEUKOPENIA; MALE; NEPHROTOXICITY; PROTEINURIA; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SOMNOLENCE; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 12244277663     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Smolen J.S., Breedveld F.C., Burmester G.R. i wsp.: Consensus statement on the initiation and continuation of tumor necrosis factor blocking therapies in rheumatoid arthritis. Ann. Rheum. Dis., 2000, 59, 504.
2. Suarez-Almazor M.E., Fitzgerald A., Grace M., Russel A.S.: Randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myocrisine) in the treatment of rheumatoid arthritis. J. Rheumatol., 1988, 15(5), 753.
3. Rau R., Herborn G., Karger T., Menninger H., Elhardt D., Schmitt J.: A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J. Rheumatol., 1991, 18(3), 328.
4. Prevoo M.L.L., van t Hoff M. A., Kuper H.H. i wsp.: Modified disease activity scores that include twenty-eigh joint counts. Arhritis Rheum., 1995, 38, 44.
5. Burmester G.R.: Molecular mechanisms of action of gold in treatment of rheumatoid arthritis - An update. Z. Rheumatol., 2001, 60(3), 167.
6. Yanni G., Nabil M., Farahat M.R., Poston R.N., Panayi G.S.: Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane Ann. Rheum. Dis., 1994, 53(5), 315.
7. Research Subcommittee of the Empire Rheumatism Consil. Gold therapy in rheumatoid arthritis: Final report of a multicentre controlled trial. Ann. Rheum. Dis., 1961, 20, 315.
8. Cutuolo M., Sulli A., Pizzorni C., Seriolo B., Straub R.H.: Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2001, 60(8), 729.
9. Świerkot J., Szechiński J., Wiland P.: Five year clinical evaluation of treatment efficacy with methotrexate in patients with rheumatoid arthritis. Pol. Arch. Med. Wewn., 2000, 103(5-6), 267.
10. Hamilton J., McInnes I.B., Thomson E.A. i wsp.: Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann. Rheum. Dis., 2001, 60(6), 566.
11. Rau R., Schleusser B., Herborn G., karger T.: Long-term combination therapy of refractory and desctructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J. Rheumatol., 1998, 25(8), 1485.
12. Knight D.M., Trinh H., Junming L. i wsp.: Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Molecular Immunology, 1993, 30, 1443.
13. Harriman G., Harper L.K., Schaible T.F.: Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFa treatment. Ann. Rheum. Dis., 1999, 58 (suppl. 1), 161
14. Lipsky P.E., Desiree M.F.M., van der Heijde D.M. i wsp.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med., 2000, 343, 1594.
15. Maini R., St Clair E.W., Breedveld F. i wsp.: Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. Lancet, 1999, 354, 1932.
16. Corkill M. E., Kirkham B.W., Chikanza I.C., Gibson T., Panayi G.S.: Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: A 24-week randomized controlled trial. Br. J. Rheumatol., 1990, 29(4), 274.
17. Heytman M., Ahern M.J., Smith R.D., Roberts-Thomson P.J.: The longterm effect of pulse corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis J. Rheumatol., 1994, 21(3), 435.
18. Menkes C.J.: Effects of disease-modifying antirheumatic drugs, steroids and non-steroidal anti-inflammatory drugs on acute-phase proteins in rheumatoid arthritis. Br. J. Rheumatol., 1993, 32 (suppl. 3), 14.
19. Vassalli P.: The patophysiology of tumor necrosis factor. Annu. Rev. Immunol., 1992, 10, 411.
20. Boerbooms A.M., Kerstens P.J., van Loenhut J.W., Mulder J., van de Putte L.B.: Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin. Arthritis Rheum., 1995, 24, 411.
21. Wolfe F., Mitchell D.M., Sibley J.T. i wsp.: The mortality of rheumatoid arthritis. Arthritis Rheum., 1994, 37, 481.
22. Stuck A.E., Minder C.E., Frey F.J.: Risk of infectious complications in patients taking glucocorticoids. Rev. Infect. Dis., 1989, 11, 954.
23. Maini R.N., Breedveld F.C., Kalden J.R. i wsp.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum., 1998, 41, 1552.